Sandoz Group Ag S/Adr (SDZNY) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Sandoz Call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you, and welcome to the Sandoz 9 Months 2025 Update Call, which focuses on sales. We plan to publish our full financial results for the year on the 25th of February. Earlier today, we published a press release and an accompanying presentation on our website, which will follow on today's call. You can find these documents at sandos.com stroke investors. Joining me on today's call are Richard Saylor, Chief Executive Officer, and Remco Steenbergen, Chief Financial Officer. Please turn to slide two. Our sales announcement, presentation, and discussion include forward-looking statements. Please see our disclaimer here. Please turn to slide three. Richard Saylor. We'll begin today's presentation with a summary of the highlights from the first nine months of the year, followed by an update on the business. Remco will cover the sales performance, as well as full year guidance. Following the wrap-up of the presentation, we'll be happy to take your questions. With that, I will now hand over to Richard. Please turn to slide four. Thank you, Greg, and hello, everyone. It is a pleasure to welcome you all to today's call, and I'm looking forward to taking you through another strong Sandoz performance. Please now turn to slide five. I am pleased that the momentum in our business has continued. We are making excellent progress on our biosimilar launches and the pipeline, as well as delivering strong, ongoing commercial execution. In the first nine months, we achieved 5% net sales growth at constant currencies, though the underlying result amounted to 6%. In Q3 alone, growth further accelerated to 6% at constant curren...